ALX Oncology Holdings Inc (NAS:ALXO)

$ 1.62 -0.07 (-4.14%) Market Cap: 85.44 Mil Enterprise Value: -49.60 Mil PE Ratio: 0 PB Ratio: 0.63 GF Score: 27/100

ALX Oncology Holdings Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
ALX Oncology Holdings Inc at UBS BioPharma Conference Transcript
Nov 08, 2023
ALX Oncology Holdings Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
ALX Oncology Holdings Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
ALX Oncology Holdings Inc Discuss The Initial AML Data From ASPEN-05 - Conference Call Transcript
Dec 13, 2022
ALX Oncology Holdings Inc at Credit Suisse Healthcare Conference Transcript
Nov 09, 2022
ALX Oncology Holdings Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
ALX Oncology Holdings Inc SITC 2021 Conference Call Transcript
Nov 09, 2021
ALX Oncology Holdings Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 08, 2021
ALX Oncology Holdings Inc to Discuss New Data from ASPEN-01 and the Phase 1b Study of ALX148 Call Transcript
Jul 06, 2021
ALX Oncology Holdings Inc Annual Shareholders Meeting Transcript
Jun 10, 2021
ALX Oncology Holdings Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2021
ALX Oncology Holdings Inc at UBS Global Healthcare Virtual Conference Transcript
May 24, 2021
ALX Oncology Holdings Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-Recorded Fireside Chat Transcript
Mar 09, 2021
ALX Oncology Holdings Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
ALX Oncology Holdings Inc at Jefferies Virtual London Healthcare Conference Transcript
Nov 19, 2020

ALX Oncology Holdings Inc Discuss The Initial AML Data From ASPEN-05 - Conference Call Transcript

Dec 13, 2022 / 12:30PM GMT

Release Date Price: $11.46 (+1.42%)

Transcript

Jeanne Y. Jew

ALX Oncology Holdings Inc. - Chief Business Officer

Good morning, and thank you for dialing in to today's conference call. I'm Jeanne Jew, Chief Business Officer of ALX Oncology. Today's call will focus on clinical data with Evorpacept, our next-generation CD47 myeloid checkpoint inhibitor from the ASPEN-05 Phase Ia dose escalation portion of the trial in AML presented at the American Society of Hematology Annual Meeting, or ASH, on December 12. A slide deck for this webcast is available on our website in the Investors Events section.

Dr. Abraham Fong, Executive Medical Director at ALX Oncology will discuss the background and biological rationale for exploring Evorpacept in combination with venetoclax and azacitidine in patients with AML. We are also privileged to be joined today by Dr. Harry Erba, Director of the Leukemia Program in the division of Hematological Malignancies at Duke University, North Carolina, who will discuss the initial dose escalation portion of the clinical trial data in patients with AML administered Evorpacept in combination with venetoclax and azacitidine.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.